美罗培南持续泵入联合注射用乌司他丁治疗重症肺炎的效果

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (640 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of continuous Meropenem pumping combined with Ulinastatin for injection in the treatment of severe pneumonia. Methods A total of 80 patients with severe pneumonia admitted to Wanbei Coal-Electricity Group General Hospital from January 2017 to September 2019 were divided into control group (40 cases) and observation group (40 cases) according to the random number table method. The control group was treated with Meropenem intravenous drip, while the observation group was treated with continuous intravenous pumping of Meropenem combined with intravenous drip of Ulinastatin for injection, and the treatment was continued for 7 days. The clinical efficacy, the removal of bacteria, the improvement time of clinical symptoms, the inflammatory indexes, lung function indexes before and after treatment and safety of the two groups were evaluated. Results The total effective rate and bacterial clearance rate of the observation group were higher than those of the control group, and the differences were statistically significant (P ＜ 0.05). The disappearance time of cough and sputum, the disappearance time of lung rales, and the time to reduce fever in the observation group were significantly shorter than those in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, C-reactive protein, tumor necrosis factor-α, interleukin-1β, and procalcitonin in the two groups after treatment were significantly lower than those before treatment, while the observation group were lower than those of the control group, and the differences were statistically significant (P ＜ 0.05). The forced end-expiratory volume in the first second, forced vital capacity, and mid-maximum respiratory flow rate of the two groups after treatment were significantly higher than those before treatment, while the observation group were higher than those of the control group, and the differences were statistically significant (P ＜ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P ＞ 0.05). Conclusion Continuous infusion of Meropenem combined with Ulinastatin for injection has a better clinical effect in the treatment of severe pneumonia, which can effectively shorten the time of clinical symptoms improvement, prompt the effect of bacterial clearance, reduce inflammatory reaction and improve lung function, and has a higher safety of medication.

Key words： Continuous infusion of Meropenem Ulinastatin Severe pneumonia Bacterial clearance rate Lung function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Weipeng WANG Lei CAI Zhenhua GUO Shengwen

Cite this article:

CHENG Weipeng WANG Lei CAI Zhenhua GUO Shengwen. Effect of continuous Meropenem pumping combined with Ulinastatin for injection in the treatment of severe pneumonia[J]. 中国医药导报, 2020, 17(25): 92-95,107.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I25/92

[1] 王明强.降钙素原、超敏C反应蛋白及D-二聚体在重症肺炎诊断和预后评估的价值[D].广州：南方医科大学，2016.
[2] 董肖萌.鲍曼不动杆菌感染临床特点及抗菌药物选择的体外研究[D].济南：山东大学，2016.
[3] 马雪，赵丽丽，越佩，等.两种不同方法输注美罗培南治疗重症感染患者的效果比较[J].中国医药，2018，13（4）：594-597.
[4] 金路，张海霞，葛卫红.肥胖危重患者美罗培南PK/PD的对照研究[J].药学与临床研究，2019，27（1）：36-39.
[5] 董印虹，向常清.脓毒症的病理及乌司他丁治疗脓毒症的研究[J].世界最新医学信息文摘，2019，19（71）：158， 160.
[6] 薛晓艳，高占成，朱继红，等.中国社区获得性肺炎诊断和治疗指南的评价[J].北京大学学报：医学版，2006，38（3）：276-279.
[7] 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中国实用乡村医生杂志，2013，20（2）：11-15.
[8] 应满珍，张为民，杜凯磊.美罗培南不同输注方式对ICU脓毒血症患者疗效对比[J].中华全科医学，2015，13（4）：553-555.
[9] 陈立，林晓洁.复方鱼腥草合剂联合阿奇霉素干混悬剂治疗儿童耐药肺炎支原体肺炎临床研究[J].国际中医中药杂志，2018，40（8）：715-718.
[10] 过晓雯，周佳.儿科美罗培南临床应用评价标准的建立与应用分析[J].中国现代应用药学，2020，37（2）：242-247.
[11] 符珏.药动学/药效学预测参数的定量分析在评价与优化哌拉西林钠舒巴坦钠抗铜绿假单胞菌感染方案中的作用[J].中国药房，2016，27（6）：777-780.
[12] 周康，李爱光.静脉滴注与持续泵入美罗培南治疗ICU重症肺炎的疗效[J].临床医学研究与实践，2018，3（26）：29-30.
[13] 余志龙，戎泽印，窦进，等.乌司他丁在胰腺癌围手术期中的临床研究[J].中华全科医学，2019，17（9）：1470-1473.
[14] 姚金帅.乌司他丁治疗急性重症胰腺炎疗效分析[J].中国冶金工业医学杂志，2019，36（5）：556.
[15] 高飞，尹纪来，王永存.乌司他丁联合奥曲肽对急性重症胰腺炎患者的临床研究[J].中国临床药理学杂志，2019，35（18）：2013-2015.
[16] 赵丽，王胜.乌司他丁脏器保护机制的研究进展[J].中华重症医学电子杂志：网络版，2019，5（3）：274-277.
[17] 辛伟，赵子明，刘芝雁，等.乌司他丁联合奥曲肽治疗急性重症胰腺炎的临床效果观察[J].中国现代医生，2018， 56（11）：95-97.
[18] 杨敏.奥曲肽、乌司他丁联合治疗急性胰腺炎的效果及对血清炎性反应的影响[J].中国医学创新，2019，16（15）：149-152.
[19] 开赛尔·艾则孜，木尼拉·亚尔买买提，杨晓红.乌司他丁对重症肺炎患者血气分析指标及血清炎性因子水平的影响研究[J].实用心脑肺血管病杂志，2016，24（2）：152-154.
[20] 牛杏果，焦宪法，郭宇红，等.乌司他丁联合注射用亚胺培南西司他丁钠对重症肺炎的疗效[J].河南医学研究，2019，28（18）：3346-3347.
[21] 李四红，周政荣.PCT、TNF-α、IL-6、IL-8和CRP水平联合检测诊断放射性肺炎合并肺部感染的临床效果探究[J].首都食品与医药，2018，25（16）：92.
[22] Sung YH，Shin MS，Ko IG，et al. Ulinastatin suppresses llipoplysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor-κB in BV2 mouse miroglial cell [J]. Int J Mol Med，2013，31（5）：1030-1036.
[23] 高莹，李丽，张云.乌司他丁可降低重症肺炎患者的血清炎性因子水平并改善肺功能[J].基因组学与应用生物学，2019，38（2）：907-910.